Arthritis drug could help treat advanced skin cancer

December 19, 2017, University of East Anglia
Arthritis drug could help treat advanced skin cancer
Credit: University of East Anglia

Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown.

The study, by scientists at the University of East Anglia (UEA), found that in mice, using the two treatments together almost completely stopped the growth of a tumour.

Although only five per cent of cases involve melanoma, it causes the majority of deaths from the disease. If caught early, melanoma is very treatable, but once the cancer has metastasised or spread, then treatment becomes more difficult.

In recent years, a number of new treatments have been developed for , some targeting certain genetic mutations. However, the disease can quickly become resistant to most drugs, so research is focusing on combinations of treatments, as lead researcher, Dr. Grant Wheeler from UEA's School of Biological Sciences, explains.

"By combining therapies, it's possible to attack the disease from several angles, which makes it harder for the melanoma to develop resistance to any of the drugs," he said.

"Our research has shown that there could also be further benefits – by joining these two drugs together you may be able to enhance their effects, getting a treatment that is more than the sum of its parts."

Dr. Wheeler, working with colleagues from Norwich Medical School and UEA's School of Pharmacy, focused on , an immunosuppressive drug approved for treatment of . Previous research by the team had shown it to be effective in use with drugs that target melanoma with a certain genetic mutation, known as BRAFV600E. Their latest research – published in the journal Oncotarget – has discovered more about how leflunomide works against melanoma and tested it in combination with another melanoma drug, selumetinib.

Selumetinib is one of a number of drugs that target the activity of a protein called MEK, to which melanoma is addicted for its survival. MEK inhibitors are already used in combination with BRAF inhibitors to combat resistance, but Dr. Wheeler's research – part-funded by the John Jarrold Trust – shows that adding leflunomide to the mix may make it even more effective.

When the team tested leflunomide in the lab, it was found to work on melanoma cells irrespective of the genetic signature of the cancer. This means that leflunomide has the potential to be used in all melanoma cases, not just for tumours harbouring BRAF mutations.

The team looked specifically at how leflunomide was acting on the melanoma cells and found that it was able to stop the cells in an early phase of their growth and then force them to kill themselves, a process known as apoptosis.

But when the scientists tested leflunomide on jointly with selumetinib, they found it was more effective than either drug on its own. This finding was replicated in tests on mice with melanoma tumours: using the two drugs together almost completely halted the growth of the tumour over a 12 day period, which far outstripped the effect of either drug used in isolation.

However, many questions remain to be answered before this combination could go into clinical trials, including testing whether melanoma can develop resistance to the .

Dr. Wheeler said: "With melanoma treatments, the main problem has been the development of tumour resistance. One way this is being combatted is through immunotherapy treatments which harness the body's own defences. However, new combination therapies are always needed and we need to identify new drugs that can be added to the arsenal of anti-melanoma therapies available for patients. It's possible that leflunomide could play that role."

"The anti-rheumatic , leflunomide, synergizes with MEK inhibition to suppress melanoma growth" is published in the journal Oncotarget on December 19, 2017.

Explore further: Role of melanoma-promoting protein revealed

More information: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget. DOI: 10.18632/oncotarget.23378

Related Stories

Role of melanoma-promoting protein revealed

December 6, 2017
In a new study, Yale researchers describe the role of a protein that promotes growth of melanoma, the deadliest form of skin cancer.

New insight into drug resistance in metastatic melanoma

June 3, 2014
(Medical Xpress)—A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

Scientists identify novel therapeutic targets for metastatic melanoma

November 27, 2017
Mount Sinai researchers have identified novel therapeutic targets for metastatic melanoma, according to a study published in Molecular Cell.

Researchers discover mechanism leading to BRAF inhibitor resistance in melanoma

June 19, 2015
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining ...

Melanoma's 'safe haven' targeted for shut-down

April 13, 2015
Melanoma cells become drug resistant by using surrounding healthy cells to provide a 'safe haven' from treatment, according to new research published in Cancer Cell today.

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Major breakthrough in quest for cancer vaccine

December 6, 2018
The idea of a cancer vaccine is something researchers have been working on for over 50 years, but until recently they were never able to prove exactly how such a vaccine would work.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.